Klotho Neurosciences remains in a high-risk, pre-revenue stage, relying entirely on external capital to fund its preclinical gene therapy research.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Benchmark GRMLW against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Greenland Mines Ltd (GRMLW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.31 | $776.08K | -0.04 | — | — | -67.62% | — | |
| $0.48 | $23.23M | -0.55 | — | — | -63.91% | — | |
| $2.45 | $42.35M | -5.35 | — | -458.48% | — | — | |
| $0.74 | $31.62M | -0.61 | — | — | — | — | |
| $2.11 | $214.74M | -4.89 | -86.92% | -181.94% | -104.05% | — | |
| $250.79 | $37.06B | 106.52 | 1.39% | 3.38% | 1.86% | — |
Greenland Mines Ltd (GRMLW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GRMLW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Greenland Mines Ltd (GRMLW) stock FAQ — growth, dividends, profitability & financials explained
No. Greenland Mines Ltd (GRMLW) reported a net loss of $21.8M over the trailing twelve months.
Greenland Mines Ltd (GRMLW) had a return on equity (ROE) of -67.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Greenland Mines Ltd (GRMLW) had negative free cash flow of $14.6M over the trailing twelve months.